Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astrazeneca Plc ADR
(NQ:
AZN
)
77.62
-0.56 (-0.72%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Astrazeneca Plc ADR
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
47
48
Next >
7 Bull Market Stocks to Buy for a Continued Run Higher in 2022
January 20, 2022
Despite surging inflation and the anticipated increase in interest rates, these bull market stocks deserve your attention.
Via
InvestorPlace
7 Bear Market Stocks to Buy If You See Trouble Ahead
January 20, 2022
These bear market stocks provide capital protection in a sharp correction scenario. They also typically have a healthy dividend yield.
Via
InvestorPlace
AstraZeneca Rolls Out "Unprecedented' Three Year Survival Data For Imfinzi/Treme Combo In Liver Cancer
January 19, 2022
A combination of tremelimumab and AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) extended the lives of newly diagnosed patients with unresectable...
Via
Benzinga
Death Cross Looms Over AstraZeneca Investors
January 19, 2022
If history is any guide, there may be trouble ahead for shares of AstraZeneca (NASDAQ:AZN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
Chopped Stocks
January 18, 2022
The day's theme is sell tech and buy banks.
Via
Talk Markets
The Week Ahead In Biotech (Jan. 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
January 16, 2022
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Here are the key catalysts...
Via
Talk Markets
The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
January 16, 2022
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss...
Via
Benzinga
Novavax Still Has Not Received an FDA EUA as the Market Waits
January 14, 2022
NVAX stock looks like a good buy here, especially if analysts' revenue forecasts for 2022 come to pass as forecast and NVAX bounces back.
Via
InvestorPlace
Two Curses Of The Current Year
January 13, 2022
The good news on inflation after this week's shocker is that December wholesale prices only rose 0.2%.
Via
Talk Markets
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
January 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...
Via
Benzinga
AstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US
January 13, 2022
AstraZeneca Plc (NASDAQ: AZN) said the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-...
Via
Benzinga
AstraZeneca's COVID-19 Vaccine Booster Against Omicron, Delta - New Data Supports Use
January 13, 2022
AstraZeneca Plc (NASDAQ: AZN) has posted preliminary data from an ongoing safety and immunogenicity trial of its COVID-19 shot, Vaxzevria. When given as a third...
Via
Benzinga
Adagio's COVID-19 Antibody Has Neutralizing Activity Comparable To Other Antibodies
January 13, 2022
Adagio Therapeutics Inc (NASDAQ: ADGI) shares gain during the premarket session after recent findings showing that ADG20 has neutralization activity against the omicron...
Via
Benzinga
Scorpion Therapeutics, AstraZeneca Ink Precision Medicines Pact For Hard-To-Target Cancer Proteins
January 13, 2022
AstraZeneca Plc (NASDAQ: AZN) has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialize precision medicines...
Via
Benzinga
The Daily Biotech Pulse: Illunina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In
January 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo...
Via
Benzinga
7 Pharmaceutical Stocks That Could Make You Rich
January 06, 2022
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich
Via
InvestorPlace
Cannabis Movers & Shakers: Aurora Bolsters Management, Curaleaf Names New Pres, Verano & Avicanna's New Appointments
January 04, 2022
Aurora Announces Changes To Management Team Aurora Cannabis Inc. (NASDAQ:
Via
Benzinga
Acasti Pharma: Bouncing Back With a New Drug Pipeline
January 04, 2022
Picture credit: Louis Reed on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial...
Via
Benzinga
Gritstone Bio's COVID-19 Booster Dose Shows Early Neutralizing Antibody Responses
January 04, 2022
Gritstone bio Inc (NASDAQ: GRTS) has shared data from the first cohort (10 µg dose) of the Phase 1 booster trial of self-amplifying mRNA (samRNA) COVID-19...
Via
Benzinga
GNPX Stock: 5 Things to Know as Genprex Rockets Higher
January 03, 2022
Shares of GNPX stock are soaring higher after the FDA granted fast track designation (FTD) for the company's lead drug candidate, REQORSA.
Via
InvestorPlace
Genprex's Lead Cancer Program Scores Second FDA Fast Track Tag For Lung Cancer Setting
January 03, 2022
The FDA has granted Fast Track Designation for Genprex Inc's (NASDAQ: GNPX) lead drug candidate, Reqorsa Immunogene combination therapy. The designation...
Via
Benzinga
Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact
January 03, 2022
Ovid Therapeutics Inc (NASDAQ: OVID) has entered into an exclusive license agreement with AstraZeneca plc (NASDAQ: AZN) for a library of early-stage small...
Via
Benzinga
Happy New Year - Sunday Edition
January 02, 2022
Starting a new year - we look at tech, pharma and mining stocks and their goings-on.
Via
Talk Markets
The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
January 02, 2022
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week.
Via
Talk Markets
The Week Ahead In Biotech (Jan 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week
January 02, 2022
Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. On the regulatory front, the Food And Drug Administration...
Via
Benzinga
2020-22: Soaring Costs Of The West's Pandemic Failure
January 02, 2022
The West failed to contain the pandemic, which has caused almost 300 million confirmed cases, 6 million deaths, and the loss of tens of trillions of dollars. For most the pandemic has been a nightmare....
Via
Talk Markets
Market Trend: Erratic And Unreliable
December 29, 2021
Given the risks of covid variants and hefty price rises, the stock market should not be as buoyant as it is.
Via
Talk Markets
Markets Inching Up
December 28, 2021
As both China and the SEC are cracking down on Variable Interest Entities raising funds as if they were stocks, these are now in the dumps.
Via
Talk Markets
Christmas is Coming
December 23, 2021
November saw a very modest increase in consumer spending, 0.6%. That means we are probably making up for it this month.
Via
Talk Markets
Oxford Lab Study Suggests AstraZeneca's COVID-19 Booster Works Against Omicron
December 23, 2021
A three-dose course of AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine is effective against the omicron coronavirus variant, data from an Oxford University lab...
Via
Benzinga
< Previous
1
2
...
28
29
30
31
32
33
34
35
36
...
47
48
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.